Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer

Can a remotely delivered weight loss intervention (WLI) reduce weight in a diverse population of women with breast cancer and a body mass index of 27 or higher?In this secondary analysis of a randomized clinical trial involving 3180 women with breast cancer, participants randomized to the WLI lost a mean of 4.3 kg, or 4.7% of their baseline body weight, at 1 year, compared to control group participants who gained an average of 0.9 kg, or 1.0% of their baseline body weight. Participants randomized to the WLI experienced significant weight loss (vs control group participants) across demographic, tumor, and treatment factors.The WLI led to statistically significant and clinically meaningful weight loss in patients with breast cancer with overweight and obesity across demographic and treatment factors.

Corresponding Author: Jennifer A. Ligibel, MD, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (jennifer_ligibel@dfci.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.